Spruce Biosciences Advances Toward MPS IIIB Therapy Approval with $69M Capital Raise
Event summary
- Spruce Biosciences closed a $69M public offering in April 2026, boosting its cash position to $107.3M as of April 30, 2026.
- The company plans to submit a Biologics License Application (BLA) for TA-ERT in Q4 2026 for the treatment of MPS IIIB.
- Spruce appointed three senior commercial leaders and two clinical development executives to prepare for potential U.S. launch.
- First-quarter 2026 R&D expenses decreased to $7.6M from $10.8M in 2025, primarily due to discontinued programs.
The big picture
Spruce Biosciences is positioning itself for a potential transformative milestone with the planned BLA submission for TA-ERT, its lead candidate for MPS IIIB. The recent capital raise and strategic hires underscore its focus on commercial readiness, but the company's success hinges on navigating regulatory hurdles and sustaining financial stability. The rare disease market remains competitive, with players like BioMarin and Reata Pharmaceuticals setting benchmarks for successful launches.
What we're watching
- Regulatory Milestones
- The pace at which Spruce advances toward BLA submission and potential FDA approval for TA-ERT will determine its commercial timeline.
- Commercial Readiness
- Whether the newly appointed commercial leadership can effectively prepare for a U.S. launch of TA-ERT, if approved.
- Financial Sustainability
- How long the current cash position and recent capital raise will sustain Spruce's operations into 2027.